Abstract 199P
Background
To evaluate the efficacy and safety of Endostar combined with concurrent chemoradiothery(CCRT) in patients with locally advanced esophageal squamous cell carcinoma(ESCC).
Methods
From May 2017 to February 2021, 90 patients with unresectable thoracic ESCC, clinical staged as IB to IVB disease based on the 8th edition of the American Joint Committee on Cancer (stage IVB:only metastasis to supraclavicular/celiac lymph nodes) and local recurrence, were enrolled and randomly allocated in Endostar plus concurrent chemoradiothery (CCRT)(intervention group; n=44) and concurrent chemoradiothery (CCRT)(control group; n=46). Five or six cycles of Endostar (7.5mg/m2/24h ×120h, 7 days/cycle) were delivered in intervention group. The primary endpoint was overall survival(OS). The secondary end-points were progression-free survival (PFS), 1-year and 2-year overall survival rate and adverse events (AE).
Results
The median age was 63(interquartile range, 50-77) years in intervention group and 65(interquartile range, 52-79) years in control group. A total of 67 patients (74%) had stage III and IV disease. The Endostar-combined group had a significant higher complete response rate(ORR) than the control group((80% vs. 63.8%; P=0.084). Survival patients had a median follow-up of 51.5 months(interquartile range: 48.2-54.8 months). The median overall survival were 16.7m in Endostar-combined group and 12.8m in control group, respectively(p=0.054). The Endostar-combined group had a significantly higher 5-year overall survival rate(13.6% vs 0%; p=0.014). The were no significant differences in the incidence of grade 3 or higher toxic effects between the intervention group and control group(P>0.05).
Conclusions
This trial shows the combination of Endostar with concurrent chemoradiotheray (CCRT) was tolerable and provided higher ORR and 5-year overall survival rate over concurrent chemoradiothery (CCRT), and is very likely to provide promising survival benefit in patients with locally advanced ESCC.
Clinical trial identification
ChiCTR-IPR-16009926.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract